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Abstract
The development of hybridoma and recombinant DNA technologies has made it possible to use antibodies against cancer, autoimmune disorders, and infectious diseases in humans. These advances in therapy, as well as immunoprophylaxis, could also
make it possible to use these technologies in agricultural species of economic importance such as pigs. Porcine reproductive and
respiratory syndrome virus (PRRSV) is an arterivirus causing very important economic losses to the industry. Passive transfer
of antibodies obtained by biotechnology could be used in the future to complement or replace vaccination against this and other
pig pathogens. To this end, we constructed and studied the properties of chimeric mouse × pig anti-PRRSV antibodies. We
cloned the constant regions of gamma-1 and gamma-2 heavy chains and the lambda light chain of pig antibodies in frame with
the variable regions of heavy and light chains of mouse monoclonal antibody ISU25C1, which has neutralizing activity against
PRRSV. The coding regions for chimeric IgG1 and IgG2 were expressed in a baculovirus expression system. Both chimeric antibodies recognized PRRSV in ELISA as well as in a Western-blot format and, more importantly, were able to neutralize PRRSV
in the same fashion as the parent mouse monoclonal antibody ISU25C1. In addition, we show that both pig IgG1 and IgG2 antibodies could bind complement component C1q, with IgG2 being more efficient than IgG1 in binding C1q. Expressing chimeric
pig antibodies with protective capabilities offers a new alternative strategy for infectious disease control in domestic pigs.
Keywords: pig chimeric antibodies, PRRSV, baculovirus

but not as efficient in the case of heterologous strains. Therefore, the high heterogeneity of PRRSV field isolates makes it
difficult to control this virus with the current vaccines.2, 3 In
fact, protective vaccines or immunization regimes inducing
the appearance of PRRSV-neutralizing antibodies against the
homologous strain are associated with protection.4, 5 The role
of neutralizing antibodies in protection of pregnant sows
from abortion6 and piglets from viremia, viral spread, and
shedding7 by passive transfer of immunoglobulins enriched
in neutralizing antibody activity has been shown previously by us. These results suggest that neutralizing antibodies could be used as immunoprophylactic pharmaceuticals
against PRRS virus infection.
The use of monoclonal antibodies against infectious diseases has been envisioned since the development of this technology.8, 9 However, it took almost 20 years until a commercial product of this sort was available to intervene in human

Introduction
The production of antibodies using recombinant DNA
technologies for therapy and prophylaxis in humans has
blossomed in the last decade, opening the door to its use in
the control of infectious diseases in animals. With such goal
in mind, it becomes important to test the feasibility of this
technology in the production of recombinant antibodies from
animals of economic importance.
Porcine reproductive and respiratory syndrome (PRRS)
is the most important infectious disease in swine, producing
losses higher than 600 million dollars per year to the industry.1 Porcine reproductive and respiratory syndrome virus
(PRRSV) is the etiological agent of PRRS. Currently, attenuated vaccines are in use to attempt protecting against PRRSV
infection. Such protection is more successful in case of infection with PRRSV strains homologous to the vaccine strain,
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infections.10 One of the main problems of this approach has
been the immune response of the nonmurine host against
mouse monoclonal antibodies. This problem was first overcome by using mouse × human chimeric antibodies and later
by “humanizing” mouse monoclonal antibodies (reviewed
in Reference 11). For example, humanized monoclonal neutralizing antibody Palivizumab (Synagis®) directed against
the F protein of respiratory syncitial virus (RSV) was the
first antibody used against infectious diseases, which has
proven successful in preventing infection of infants at risk.12
Currently, many antibodies obtained by recombinant DNA
technology are available in human medicine against cancer,
autoimmune, and infectious diseases. The knowledge accumulated about mouse and human antibodies’ sequence,
structure, and function of the different domains of the molecule has been important in the design and development of
this new kind of prophylactic and therapeutic biologics.
Herein we show that it is feasible to produce mouse ×
pig chimeric antibodies in a baculovirus expression system
that maintains the same properties of the Fv from mouse antibodies. We also show the ability of the Fcs of pig IgGs to
bind C1q of complement. Such preservation of the properties
of the mouse × pig chimeric antibodies allow for a new possible strategy against PRRSV in pigs to provide immediate
prevention of infection.
Materials and Methods
Cloning of constant regions of porcine lambda, gamma-1 and
gamma-2 chains
Sequences encoding porcine heavy and light chain constant regions were amplified from RNA, using primers
based on the published sequences for gamma and lambda
chains.13, 14 Standard cloning procedures were carried out.15
Briefly, total RNA was isolated with TRIZOLTM (Gibco-Invitrogen, CA, USA) from spleen obtained by necropsy of a
healthy, 4-month-old large-white pig. Reverse transcription reactions were performed using SuperScriptTM (Invitrogen, CA, USA) for 50 min at 42°C and primers for porcine
gamma-1 and gamma-2 (5′-TATGTACACAGCGCTGGGGC3′) and for porcine lambda chain (Oligo-dT). PCR were performed using Pfu DNA Polymerase (Stratagene, CA, USA) in
the manufacturer’s buffer using forward 1-19 Nhe I (5′-GCTAGCGCCCCCAAGACGGCCCCAT-3′) and reverse 977-999
Kpn I (5′-GGTACCGCAGCGGGTGGCTCATTTACCCT-3′)
primers for porcine gamma-1, forward 1-19 Kpn I (5′-GCTAGCGCCCCCAAGACGGCCCCAT-3′) and reverse 969988 Kpn I (5′-GGTACCTCATTTACCCGGAGTCTTG-3′) for
porcine gamma-2, and forward 19-42 Hpa I (5′-ACTGTTAACCTCTTCCCGCCCTCC-3′) and reverse 301-318 Bgl II
(5′-AGATCTCTAGGCGCACTCGGAGGG-3′) for lambda
constant chains. Recognition sites for the restriction endonucleases are shown in italic font. The three DNA fragments
were cloned in pGEM®-T Easy Vector (Promega, WI, USA).
Cloning of variable regions of murine lambda and gamma-1 chains
Heavy and light chain variable regions were amplified
from hybridoma ISU25C1.16 ISU25C1 monoclonal antibodies use gamma-1 and lambda chains and recognize an epitope located at the ectodomain of glycoprotein GP5 from
PRRSV strain KY35 (NVLS 46907). Mouse heavy chain vari-

able region was amplified by RACE-PCR (5′ RACE System
for Rapid Amplification of cDNA Ends, Version 2.0; Invitrogen) from total RNA. cDNA was synthesized using a primer
annealing between nucleotides 82 and 99 of the mouse antibody gamma-1 chain (5′-GAAATAGCCCTTGACCAG-3′).
PCR amplification of dC-tailed cDNA was performed using
Abridged Anchor Primer (provided by the kit) and a reverse
primer annealing between nucleotides 40 and 62 (5′-GAGTTAGTTTGGGCAGCAGATCC-3′). Whole mouse lambda
chain was amplified by RT-PCR. cDNA was synthesized using oligo-dT, and PCR was performed with a forward primer
1-18 (5′-ATGGCCTGGAYTTCACTT-3′) designed based on
the sequences for leader peptides of mouse lambda-1 and
lambda-2 variable regions17, 18 and reverse primers for mouse
lambda-1 687-705 (5′-CTAGGAACAGTCAGCACG-3′) and
mouse lambda 2 685-705 (5′-TTAGAGACATTCTGCAGGAGA-3′), based on the published antibody lambda constant regions.19 The amplified DNA fragment was cloned in
pGEM-T Easy Vector (Promega Corp.).
Construction of recombinant baculoviruses for the production of
chimeric IgG1 and IgG2
The assembly of variable and constant heavy and light
chains as fusion proteins is described in the “Results” section. The DNA sequence coding for complete chimeric light
chain was released from pGEM-T Easy vector (Promega)
and cloned at the Bgl II site in baculovirus transfer vector
pAcUW51 (Pharmingen, CA, USA) to obtain vector pAcISU25-PIGλ. DNA sequence for complete chimeric heavy
chains (gamma-1 and gamma-2) were then released from TA
vector and cloned at the BamH I site in vector pAc-ISU25PIGλ, to obtain vectors pAc-ISU25-PIGλ/γ1 and pAc-ISU25PIGλ/γ2, respectively, carrying the encoding sequences for
chimeric [mouse × pig] IgG1 and IgG2 complete antibodies.
The inserts were sequenced seven times and no unexpected
mutations were introduced during the cloning procedure.
Production and purification of chimeric IgG1 and IgG2
Sf 9 cells were cotransfected with vectors pAc-ISU25PIGλ/γ1 or pAc-ISU25-PIGλ/γ2 and BaculoGold® linearized
baculovirus DNA (Pharmingen) by the calcium phosphate
method, following the instructions of the manufacturer. Recombinant viruses produced by homologous recombination and carrying the sequences for chimeric IgG1 and IgG2
were obtained from supernatants 4 days post-transfection,
plaque-purified, and amplified to produce a high titer viral
stock. Intracellular expression of chimeric immunoglobulins
in infected cells was assessed by immunofluorescence using
a FITC-conjugated anti-pig IgG (H+L) (KPL, MD, USA). Sf 9
cultures at a density of 2 × 106 cells/mL were infected with
recombinant viruses at a multiplicity of infection (m.o.i.) of 5
and grown in serum-free medium (Sf-900 II SFM, Gibco-Invitrogen) at 26°C over a shaking platform. After 5 days of culture (~50% of dead cells), cultures were harvested and clarified by centrifugation at 10,000g for 5 min. The virus and
other large particles were pelleted by ultracentrifugation at
40,000g for 30 min. The supernatants were concentrated by
ultrafiltration using 80-mL recipients (Centricon-80, Millipore Corp., MA). Samples were centrifuged at 3,000g for 2
h, resuspended in PBS, and centrifuged again to concentrate
100 times the antibodies in the supernatant. Alternatively,
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recombinant antibodies were applied to Protein A-Agarose packed in Econo-columns (Bio-Rad Laboratories, CA).
Bound IgG was eluted with 0.1 M glycine buffer pH 2.5.
Characterization of chimeric IgGs by SDS-PAGE and Western
blot analysis
Standard procedures were performed according to Harlow and Lane.20 Chimeric IgG1 and IgG2 affinity-purified
by Protein-A columns and controls, 500 ng of protein per
lane, were analyzed under reducing conditions on 15% polyacrylamide gels stained with Coomassie Brilliant Blue R250
(Pierce, IL, USA). Porcine serum antibodies used as positive
controls were purified by ammonium sulfate precipitation
and affinity-purification through protein A-agarose columns.
Supernatant from Sf9 cells infected with a recombinant baculovirus producing an unrelated protein (Xyl-E) was used as
negative control. Western blots were performed using HRPconjugated antibodies and developed by chemiluminescence
(Lumi-Glo®, KPL) on a classic autoradiography single-emulsion film (Midwest Scientific, MO, USA).
Chimeric antibodies chains were identified in Western
blot analyses by an anti-porcine IgG (KPL) and commercial
monoclonal antibodies identified as heavy-chain specific for
porcine IgG1 (Cat. no. MCA635; clone K139 3C8) and porcine
IgG2 (Cat. no. MCA636; clone K68 Ig2) and specific for porcine Lambda chain (Cat. no. MCA633; clone K139 3E1) from
Serotec Ltd., Oxford, UK. The three monoclonal antibodies
have an IgG1/kappa isotype; then, a rat anti-mouse kappa
horseradish peroxidase (HRP)-conjugated antibody (Cat. no.
MCA1291P, Serotec Ltd.) was used as secondary antibody. A
Western blot using glycosilated and deglycosilated porcine
total IgG was performed to assess whether different glycosilation pattern in insect cells could affect the recognition of
monoclonal anti-porcine IgG1 or IgG2. Two polyclonal IgG
samples, purified from serum pools, were treated with Nglycanase [Peptide-N4-(acetyl-β-glucosaminyl)-asparagine
amidase] (PROzyme, CA). Two micrograms of treated and
untreated IgG were run on a 10% polyacrylamide gel, and its
Western blot was performed as described earlier.
Production of PRRS virus
PRRSV strain KY35 (NVLS 46907) was used as antigen
throughout this work. Virus was grown in MARC-145 cells
infected at an m.o.i. of 0.1 when cultures reached a confluence of 90-95% and harvested when the cytopathic effect
reached 80% (~5 days p.i.). PRRSV was used either as a clarified suspension (cell associated virus: CAV) or purified by
ultracentrifugation on a 40% sucrose cushion. Peptide S4
(SHITSYPAYFWC), a mimotope corresponding to epitope
B on glycoprotein GP5 from PRRSV strain KY35, was produced by chemical synthesis.
PRRSV-ELISA
The ability of chimeric IgG1 and IgG2 to recognize complete virus was assessed by ELISA analysis. Chimeric antibodies from ultrafiltered supernatants were used as primary
antibodies, followed by a goat anti-porcine IgG, HRP conjugated (KPL Inc.). Monoclonal antibody ISU25C1 was used
as positive control, followed by a HRP-conjugated goat antimouse IgG (KPL Inc.). Ultrafiltered supernatant from Xyl-E
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producing Sf9 cells was used as negative control.
Reactions were performed using standard procedures.20
ELISA plates (Immulon 2 HB; ThermoElectron Corp., MA,
USA) were coated with 5 μg of CAV-PRRSV or uninfected
cells in sodium carbonate buffer, pH 9.6. Chimeric antibodies
or control Xyl-E were detected with a HRP-conjugated antiporcine IgG (H+L) antibody (KPL Inc.), and monoclonal antibodies were detected with an HRP-conjugated anti-mouse
IgG (H+L) antibody (KPL Inc.), both at a dilution 1:1,000. Reactions were developed with ABTS (KPL Inc.), stopped with
1% SDS and read at 410 nm. The absorbance read for PRRSVinfected cells was compared with the absorbance read for
MARC-145 non-infected cells. Values of optical densities
(ODs) read at 410 nm are expressed as corrected OD, calculated as ½ [(OD Ms - OD Mc)+(OD ms - OD mc)], where Ms
and ms are the maximum and minimum values for the samples while Mc and mc are the maximum and minimum values for the controls, respectively.
PRRSV-epitope B ELISA
A peptide-ELISA was performed to determine the ability
of mouse × pig chimeric antibodies to recognize peptide S4
(SHITSYPAYFWC), as described earlier.21 Reacti-Bind Maleimide-Activated Plates (Pierce Biotechnology, Rockford,
IL) were coated during 6 h with 2.5 μg of either peptide S4 or
irrelevant peptide P7 (QRAYLELPPWPPC) in PBS at pH 6.8.
Both peptides carry a terminal cysteine that allows binding
to activated plates through stable thio-ether bonds at neutral
pH. Free maleimide groups were blocked by 1-h incubation
of 10 μg/mL cysteine-HCl in PBS at pH 6.8. After a second
blocking step with 10% skim milk in PBS, ELISA was carried
out following the ELISA protocol described earlier. Again,
values of absorbance at 410 nm were expressed as corrected
OD as described earlier.
Western blot analysis
Western blots were performed with CAV-PRRSV as well
as sucrose-purified PRRSV. Chimeric antibodies were detected with an HRPO-conjugated anti-porcine IgG (H+L) antibody (KPL Inc.) while monoclonal antibody ISU25C1 was
detected with an HRP-conjugated anti-mouse IgG (H+L) antibody (KPL Inc), both at a dilution 1:1,000. Reactions were
developed by chemiluminescence or through a precipitating substrate (TMB 1-component Membrane Peroxidase Substrate; KPL Inc.).
Neutralization of PRRSV
The efficiency of chimeric antibodies on PRRSV neutralization was evaluated through a fluorescent foci reduction
assay measured 24 h p.i. A viral focus was defined as four or
more infected cells identified by an immunofluorescence reaction in the cell cytoplasm. PRRSV was used at a concentration of 50-100 foci forming units (FFU) in a volume of 50
μL. The percent of neutralization was obtained comparing
the average foci number detected when ultrafiltered supernatants with chimeric IgG1 and IgG2 were added to PRRSV
(sample), vs. the average foci number documented when
only RPMI medium was added (control). Ultrafiltered supernatant containing the nonrelated protein Xyl-E and ammonium sulfate-precipitated IgG, purified from a pool of normal
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(nonimmune) sera, were used as negative controls. Monoclonal antibody ISU25C1 and ammonium sulfate-precipitated
IgG purified from a pool of hyperimmune sera were used as
positive controls. Immunofluorescence was performed with
monoclonal antibody SDOW17 (National Veterinary Laboratory Services, NVLS, USDA, IA) that recognizes a highly
conserved epitope on PRRSV nucleocapsid protein 22 and a
fluorescein-conjugated anti-mouse IgG (H+L) antibody (KPL
Inc.). Results are expressed as inhibition percentage in FFU
as determined by the immunofluorescence assay, after the
formula: 100 × sample FFU × (control FFU-1).

Table 1. Constant Heavy Chain in Chimeric IgG2 Compared to
IgG2a and IgG2b (Aminoacid Multiple Alignment)

ELISA tests for assessing C1q Binding

(GenBank no. U03780). Paired comparison with gamma-2a
showed nine differences between nucleotides and three amino
acid substitutions, 15 G →S, 18 V→T and 47 T →S, while comparison with gamma-2b showed five differences at the nucleotide level and two substitutions at the amino acid level, 7 S →
L and 18 V →T (Table 1). All these differences are located in
the CH1 domain of the molecule. Thus, this sequence represents a mixture of those described as gamma-2a and gamma2b, and it was named as “Gamma2.” This sequence is available from GenBank under accession number EU479715.
Analysis of the sequences of the variable heavy and
light chains from hybridoma ISU25C1 indicated that the
heavy chain is encoded by a J558.50 VH gene (Genbank no.
AF303881), a DSP-9 D gene (Genbank no. D13199), and a JH2
(Genbank no. V00770) gene with three aminoacid substitutions to the VH gene, two in framework 1 at positions 13 (G
→R) and 28 (T →I) and one in CDR2 at position 57 (D →G),
but no changes in the D and JH genes (Figure 1, Supporting Information). Analysis of the light sequence indicated a
lambda-1 chain using the Vλ1 gene (Genbank no. V00811)
and Jλ1 (Genbank X58419) with an aminoacid substitution (A
→P) at position 28 in the CDR1 (Figure 2, Supporting Information). Based on this information, a strategy for cloning the
mouse variable genes in frame with the pig constant genes
was designed.
Figure 1 (left panel) shows the flowchart and strategy used
to clone mouse Vλ in frame with porcine constant lambda
and mouse VH coding regions in frame with porcine constant
gamma-1 and gamma-2. To clone the mouse lambda variable
gene used by monoclonal antibody ISU25C1 in frame with the
pig lambda constant genes, we took advantage of the presence
of a VN aminoacid sequence at positions 8-9 of the constant
region of pig lambda sequence (GTCAAC) and changed it for
a Hpa I restriction endonuclease recognition site (GTTAAC)
without changing the IgG pig aminoacid sequence. We incorporated this Hpa I sequence in the 3′ end of the reverse primer
for the mouse lambda chain variable region, and the 5′ end of
the forward primer for the pig lambda chain constant region.
All mouse variable heavy antibodies end with either aminoacids VSS or VSA. Mouse VH region used by monoclonal antibody ISU25C1 was reamplified placing an Xba I restriction
endonuclease recognition site in the 3′ of the VH gene, corresponding to the last two codons of the variable coding region. The VH was cloned in frame with gamma genes using
a Nhe I restriction endonuclease recognition site in the 5′ of
the gamma regions, restoring the original Ser-Ser aminoacids
at the end of the JH coding region.
A restriction endonuclease recognition site for Bgl II was
inserted 5′ to the sequence coding for the VL leader peptide and 3′ to the lambda chain stop codon, while a restric-

A dot-ELISA was developed to assess the ability of chimeric antibodies to bind the complement component human C1q, using chimeric IgG1 and IgG2 affinity-purified
through protein-A agarose columns followed by ultrafiltration to concentrate the purified proteins. A porcine-IgG standard (Cat. no. P100-105, Bethyl Laboratories, TX) was used
as positive control, and a human-IgA standard (Cat. no.
P80-102, Bethyl Laboratories, TX) was used as negative control. Two microliters of twofold dilutions (starting at 1 μg/
μL) of each antibody were dotted on nitrocellulose membranes at 37°C in a humid chamber during an hour. Membranes were gently washed with PBS Tween 20 (PBST) and
blocked at 4°C overnight with 10% skim milk in PBST. Human serum (Cat. no. S-1764, Sigma, MO, USA) was used as
source of C1q, at a 0.2% concentration in PBST with 5% skim
milk. C1q binding to membrane-absorbed immunoglobulins
was detected with an anti-human complement C1q goat antibody (Fraction IgG) FITC-conjugated (Cat. no. 55166, ICN
Pharmaceuticals, OH, USA) diluted 1:2,000, followed by an
anti-FITC monoclonal antibody alkaline phosphatase-conjugated (Clone FL-D6, Sigma A-1812, Sigma) in a 1:30,000 dilution. On each step, membranes were incubated during 1
h, followed by a 15-min and two 5-min manual washes with
PBST. Dot-ELISA was developed with BCIP/NBT (KPL Inc.).
Each sample was studied in duplicates, and the whole experiment was repeated two independent times.
An ELISA test was performed coating 96-well microplates
with chimeric or standard antibodies and then following the
same procedure described for the Dot-ELISA. Immulon®
2HB plates (ThermoElectron Corp) were sensitized overnight
at 4°C with twofold dilutions of each antibody in 10 mM carbonate buffer, pH 9.2. Human serum complement was added
at a dilution 1:250 (0.4%), anti-human complement C1q was
used at a 1:1,000 dilution and monoclonal anti-FITC alkaline
phosphatase-conjugated antibody was used at a 1:10,000 dilution. Each reagent was diluted in PBST-5% skim milk and
incubated for 1 h at room temperature under shaking. Plates
were manually washed six times after each step, developed
with a soluble form of BCIP substrate (Blue-Phos Microwell
Substrate Kit; KPL Inc.) and read at 650 nm.
Results
Cloning and expression of chimeric IgG1 and IgG2
Porcine constant lambda and gamma-1 were identical
to the reported sequences posted at GenBank (M59322 and
U03778, respectively). Porcine gamma-2 showed 99% identity
with both gamma-2a (GenBank no. U03779) and gamma-2b

Sequence, Author
(GenBank Accession No.)
IgG2, this paper (EU479715)
IGg2a, Kacskovics 13 (U03779)
IgG2b, Kacskovics 13 (U03780)

Amino Acid Residue
007

015

018

047

S
S
L

G
S
G

V
T
T

T
S
T

Val 18 in IgG2 is coded by GTG while Thr 18 in both IgG2a and
IgG2b is coded by ACG.
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Figure 1. Flow chart and strategy to clone chimeric mouse × pig IgG1 and IgG2 antibodies.Left panel shows primers used to amplify the
3′ end of variable regions and the 5′ end of constant regions, to clone in frame variable and constant regions in chimeric lambda-1 chain
(upper left) or gamma-1 and gamma-2 chains (lower left). Right panel shows flow chart to clone complete chimeric light and heavy chains
in baculovirus transfer vector pAc-UW51.

tion endonuclease recognition site for BamH I was inserted
5′ to the sequence coding for the VH leader peptide and 3′
to the gamma chains stop codons, to allow cloning complete lambda and gamma chains coding sequences in Bgl II
and BamH I cloning sites at baculovirus transfer vector pAcUW51 (Figure 1, right panel).
Chimeric antibodies obtained from the supernatants of
baculovirus infected-Sf9 cell cultures and purified by ultrafiltration reached concentrations of 30 to 100 μg/mL.
Gamma-1 and gamma-2 chains from chimeric antibodies
showed to be slightly lighter than heavy chains from porcine
a Western blot (Figure 2, left panel). Monoclonal antibody

Figure 2. Western blot analysis of baculovirus-expressed mouse
× pig chimeric antibodies developed with chemoluminiscense using anti-porcine IgG (H+L) (left panel), anti-porcine IgG1 (middle
panel), and anti-porcine IgG2 (right panel).Lane 1: chimeric IgG1/
lambda; Lane 2: chimeric IgG2/lambda; Lane 3: porcine purified
Igs (0.5 μg/sample).

serum but were recognized by an anti-porcine IgG (H+L) in
K139 3C8 (anti-porcine IgG1) recognized chimeric gamma1 and not gamma-2 (Figure 2, middle panel), while monoclonal antibody K68 Ig2 did not recognize either gamma-1
or gamma-2 (Figure 2, right panel) but did recognize heavy
chains from purified serum IgG. This lack of recognition was
not due to the different glycosilation pattern showed by chimeric gamma-2 produced in insect cells. K68 Ig2 recognized
both glycosilated and deglycosilated porcine total IgG in a
Western blot (Figure 3, Supporting Information). To determine the target for K68 Ig2, we tested it against IgG4, since
this is the closest to IgG2 in sequence.13 We cloned both porcine IgG2 and IgG4 in Vector pGEMEX®, expressed them
in E. coli and run them in a Western blot. It was shown that

Figure 3. Mouse × pig-chimeric antibodies recognize PRRSV’s
GP5.Left panel: PAGE; Middle-left panel: Western blot developed
with chimeric IgG1; Middle-right panel: Western blot developed
with chimeric IgG2. Right panel: Western blot developed with
monoclonal antibody ISU25C1. Lane 1: PRRSV-infected cells, Lane
2: Noninfected cells, Lane 3: MW Marker (116-66.2-45-35-25 kDa),
Lane 4: purified PRRSV. Arrow shows apparent molecular weight
of 25 kDa
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in PRRSV infected MARC-145 cells as well as sucrose-purified PRRSV (Figure 3). In a peptide-ELISA format (Table 2,
right column) mouse × porcine chimeric antibodies recognized the PRRSV-GP5 mimotope represented by peptide
S4, the same epitope recognized by monoclonal antibody
ISU25C1.21 This peptide-ELISA was developed with peroxidase-conjugated anti mouse (H+L) or anti-pig (H+L) antisera
as secondary antibodies. Hyperimmune serum from PRRSV
infected pigs with a neutralization titer of 256 also recognized S4 in a peptide-ELISA format using the same peroxidase-labeled anti-pig antiserum used with chimeric antibodies. Thus, mouse × porcine chimeric antibodies recognized
the same protein and epitope as ISU25C1.
Figure 4. PRRSV neutralization by chimeric antibodies IgG1 and
IgG2.Results are expressed as the inhibition percentage in viral
foci forming units detected in an immunofluorescence assay (see
Materials and Methods).

monoclonal antibody K68 Ig2 recognized IgG4 heavy chain but
not IgG2 heavy chain cloned and expressed in the same system (Figure 4, Supporting Information). The main differences
between the sequence of chimeric IgG2 and IgG4 reside on the
CH3 domain (94% identities for aminoacids) and possibly this
could be the area recognized by this monoclonal antibody.
Mouse × porcine chimeric antibodies recognize the epitope in
PRRSV described for monoclonal antibody ISU25C1
Both chimeric antibodies recognized PRRSV-infected
MARC-145 cells by ELISA. Values shown on Table 2 (left column) correspond to a representative experiment of six independent experiments and are expressed as the normalized
OD between PRRSV-infected and noninfected MARC-145
cells. Protein Xyl-E secreted by baculovirus-infected cells
concentrated using the same methodology as for the chimeric antibodies was used as a negative control. Cell-culture supernatant from hybridoma ISU25C1 was used as a positive
control but was developed with an anti-mouse (H+L) peroxidase-conjugated antiserum as secondary antibody. Positive (hyper-immune) or negative (nonimmune) porcine sera
could not be used in this ELISA because both showed very
high background signals against noninfected cells (data not
shown). In addition, both chimeric IgG1 and IgG2 antibodies
recognized a linear epitope of glycoprotein GP5 (25 kDa), the
same protein recognized by monoclonal antibody ISU25C1,
Table 2. Chimeric Antibodies Recognize Cell-Associated (CAV)PRRSV in an ELISA Test and Peptide S4 (PRRSV-GP5 Mimotope) in a
Peptide-ELISA Test
Sample
IgG1 (1.5 μg/mL)
IgG2 (1.5 μg/mL)
Xyl-E (1.5 μg/mL)
Hyperimmune serum
Negative serum
ISU25-C1
K99

ELISAa
1.132 (±0.044)
1.417 (±0.028)
–0.032 (±0.002)
ND
ND
1.980 (±0.002)
–0.008 (±0.003)

Peptide-ELISAb
0.753 (±0.045)
0.689 (±0.039)
ND
1.400 (±0.109)
0.195 (±0.019)
1.150 (±0.032)
0.085 (±0.006)

Values of optical densities (ODs) read at 410 nm are expressed as normalized OD (±SD), calculated as ½ [(OD Ms – OD Mc) + (OD ms – OD
mc)], where Ms and ms are the maximum and minimum values obtained for the samples (a) CAV-PRRSV or (b) Peptide S4, while Mc and
mc are the maximum and minimum values obtained for the controls
(a) noninfected cells or (b) peptide P7. ND, not done.

Mouse × pig chimeric IgG1 and IgG2 neutralize PRRS virus
Cell culture supernatant from hybridoma ISU25C1 inhibits the production of 60% of viral foci when 100 FFUs of
PRRSV are added to MARC-145 cells.16 Supernatants from
baculovirus infected-Sf9 cells containing chimeric IgGs,
semipurified and concentrated by ultrafiltration at a concentration of 15 μg/mL, produced an inhibition in viral foci
formation that averaged an inhibition of 56% for IgG1 and
53% for IgG2 in three different independent experiments, using at least three wells per sample (Figure 4). Supernatants
from baculovirus infected-Sf9 cells containing unrelated XylE protein, also semipurified by ultrafiltration, in the same
concentration produced no reduction in FFUs. Thus, besides
recognition of the same epitope than the original monoclonal antibody ISU25C1, mouse × pig chimeric antibodies also
neutralize PRRSV in a similar fashion as ISU25C1.
Hyperimmune Igs rendered 95% reduction in viral foci at
a concentration of 60 μg/mL, while nonimmune Igs rendered
no neutralization even at a concentration of 220 μg/mL.
Chimeric IgG1 and IgG2 bind human complement C1q
To test the binding capabilities of pig gamma-1 and
gamma-2 to C1q of human complement, antibodies were
studied by ELISA and Dot-ELISA. Complement binding
was assessed by addition of a goat anti-human C1q FITCconjugated antibody followed by a peroxidase-conjugated
anti-FITC monoclonal antibody. These experiments showed
that both pig IgG1 and IgG2 bind human C1q component of
complement, with IgG2 being two times more efficient than
IgG1 (Table 3 and Figure 5, Supporting Information). Standard porcine IgG behaved in a similar manner than chimeric IgG2. Chimeric IgG2 showed OD values 2.4 times higher
than chimeric IgG1, while standard porcine IgG showed OD
values 1.8 times higher than chimeric IgG2. Similar results
were obtained in a Dot-ELISA format (Figure 5, Supporting
Information).
Table 3. ELISA to Detect C1q Binding to Chimeric IgG1 and IgG2
Concentration
(mg/mL)
IgG1
0.50
0.25
0.12
0.06

0.053 (±0.025)
0.040 (±0.023)
0.029 (±0.019)
0.015 (±0.022)

IgG2
0.130 (±0.026)
0.096 (±0.007)
0.031 (±0.011)
0.002 (±0.008)

Standard
Porcine IgG
0.232 (±0.021)
0.176 (±0.018)
0.069 (±0.008)
0.026 (±0.009)

ELISA to detect C1q binding to chimeric IgG1 and IgG2. Standard porcine IgG was used as positive control. Results are expressed as normalized OD (±SD).
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Discussion
In this article, we showed that mouse × pig chimeric antibodies can be expressed maintaining the binding properties
of the mouse Fv as well as properties of the pig constant regions such as complement activation.
The classification of pig IgG subtypes is still under discussion.13, 23 We produced two chimerics using the constant
regions of pig IgG1 and IgG2. The rationale of this selection is based on the fact that at the aminoacid level IgG2a/
IgG2b and IgG4 have a 94% of identity while IgG1 and IgG3
have a 96% of identity, compared to 87% of identity between IgG1 and IgG2a/IgG2b. This data suggest that the
two (IgG1 and IgG2) are truly different subisotypes of pig
immunoglobulins.
Mab K139 3C8 recognizes pig IgG1 but not IgG2 while
Mab K68 Ig2 does not recognize IgG1 or IgG2 (Figure 2).
Since IgG4 is the closest to IgG2 in sequence,13 we cloned
and expressed both IgG2 and IgG4 in bacteria. This IgG4 is
recognized in a Western blot by K68 Ig2 monoclonal antibody while IgG2 is not. The main differences between the sequences of chimeric IgG2 and IgG4 resides on the CH3 domain (94% identities for aminoacids) and possibly this could
be the area recognized by this antibody.
The induction of different IgG subclasses has been correlated with protective immunity in mice,24 humans,25 cattle,26
and other species, but not in pigs. The expression of chimeric mouse × human antibodies has been useful for the understanding of the functions of the different IgG subclasses.27, 28
The expression of chimeric mouse × pig IgG antibodies helps
in the knowledge of the functions of pig IgGs as well as the
characterization of these molecular defined antibodies,29 and
it is a byproduct of this work. To determine the capabilities of
chimeric pig IgG1 and IgG2 to activate complement using the
classical pathway, C1q was added to the chimeric antibodies in
an ELISA and Dot-ELISA formats (Table 3 and Figure 5, Supporting Information). These experiments showed that IgG2
binds complement up to four times better than IgG1. These results are in agreement with previous research that showed that
IgG2 obtained from pig serum is more efficient in activating
complement that IgG1 measured by lysis of red blood cells.30
These authors postulated that the higher flexibility shown by
the aminoacids present at the hinge of IgG2 and IgG4 allows
for better activation of complement. Thus, the better activation
of complement by IgG2/IgG4 might be due to C1q activation,
and the expression of chimeric mouse × pig antibodies does
not impair this property located in the CH2 domain.
ISU25C1 binds to an area of GP5 of PRRSV that we previously named epitope B and is the immunodominant neutralizing epitope of PRRSV.21, 31 The Fv mouse antibody fragments expressed as chimeric antibodies recognize the same
epitope as the original mouse monoclonal antibody ISU25C1
as demonstrated by recognition of PRRSV-infected cells in an
ELISA format as well as the peptide S4 in a peptide-ELISA
format (Table 2), and PRRSV-GP5 in a Western blot format
(Figure 3). Moreover, chimeric antibodies neutralize PRRSV
(Figure 4) similar to the parent mouse monoclonal antibody
ISU25C1. Thus, expression of mouse Fvs in-frame with pig
IgG antibodies does not impair the paratope of the mouse
antibodies or the function of neutralization located in this
fragment of the parental mouse antibody.
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Neutralizing monoclonal antibodies available against
PRRSV, including ISU25C1, have low neutralizing activity.16, 32 The VDJ gene of ISU25C1 presents two mutations
in framework 1 and one in CDR2 compared to putative VH
gene J558.50 and the use of D gene DSP9 read in the third
reading frame without mutations (Figure 2, Supporting Information). The low mutation rate in the complementarity
determining regions of this antibody suggests that there is
no affinity maturation involved in this antibody induced in
mice by hypermutation. It seems that the presence of sugars in the area around epitope B covers this epitope from
antibodies, since a mutant depleted of glycosylation at positions 34 and 51 is more immunogenic in pigs.33 This glycan shielding strategy seems to be also used by HIV and
represents an obstacle to develop neutralizing antibodies
against HIV in mice.34 The production of next generation
mouse hybridomas using deglycosilated PRRSV as immunogen would allow for broad and more potent neutralization monoclonal antibodies against PRRSV. These hybridomas could be used in the future as donors of VH-VL
genes for the construction of mouse × pig chimeric neutralizing antibodies against PRRSV using the vectors described
here.
Epitope B is also the target to neutralizing antibodies induced in pigs, though the area recognized by these antibodies is different.21 This difference might be related to differences in the generation of antibody diversity in pigs.35, 36 It
is now possible to produce Fvs libraries of pig antibodies.37
The combination of this technology with the one described
here would allow for the production and expression of 100%
pig antibodies against PRRSV.
Here we show that chimeric mouse × pig antibodies do
maintain the same properties that the parent domains. The
production of recombinant antibodies as prophylactic and/
or therapeutic tools in humans has blossomed in the last 10
years. So far, these antibodies are produced in mammalian
cells, but different approaches to produce in other less expensive systems are under experimentation. The production
in insect cells has shown to be quite expensive and still with
unpredictable results. Plants seem to be systems that could
produce high quantities at low price and expression has been
improved in the last few years.38 Thus, chimeric antibodies
could be used as preventive and therapeutic tools in animals
of economic importance when the technology to produce
these antibodies becomes more cost effective. The method
used in these experiments would be a universal method for
construction of mouse × pig chimeric antibodies. This strategy could be used alone or accompanying other strategies
as vaccination to provide instant immunity in the face of an
outbreak and before the establishment of effective adaptive
immune response of the pig.
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